Nano Holdings, Inc. (4571)

Market cap
¥10.6B
P/E ratio
-10.2x
NANO MRNA develops RNA-based drug candidates including mRNA and siRNA therapies, then licenses them to pharmaceutical companies for late-stage development and commercialization.
Period EndNet income margin (%) YoY (%)
Mar 31, 2025-769.8+33.74%
Mar 31, 2024-575.6-11.22%
Mar 31, 2023-648.4-9.02%
Mar 31, 2022-712.7-21.27%
Mar 31, 2021-905.2+149.08%
Mar 31, 2020-363.4-0.18%
Mar 31, 2019-364.1-82.59%
Mar 31, 2018-2,090.6+70.85%
Mar 31, 2017-1,223.6+17.36%
Mar 31, 2016-1,042.6+3301.31%
Mar 31, 2015-30.7-87.00%
Mar 31, 2014-235.9+81.97%
Mar 31, 2013-129.6+12.79%
Mar 31, 2012-114.9
AI Chat